Actively Recruiting
Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study
Led by Istituto Ortopedico Rizzoli · Updated on 2026-05-12
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the use of arterial embolization as a minimally invasive treatment for bone metastases. This approach is popular because it may help reduce pain, control the disease locally, and decrease bleeding during surgery with minimal invasiveness. The study is observational and aims to gather data on these outcomes in patients who receive embolization therapy. Participants in this study will undergo arterial embolization targeting bone metastases. The study does not involve randomization or comparison groups, as it observes the effects of this treatment in routine clinical practice. The focus is on patients who are candidates for embolization therapy, including those with single or multiple metastatic sites causing pain or risk of bone fracture. During the study, participants will be evaluated for changes in pain levels using the Visual Analog Scale (VAS) and improvements in quality of life through the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL questionnaires over one year. Researchers will also measure tumor volume reduction at one year. The study will monitor patients' health and quality of life while assessing the impact of embolization on bone metastases over this period.
CONDITIONS
Brief Title
Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of either sex aged 18 or older who are candidates for embolization therapy
- Life expectancy greater than 3 months
- Single metastatic or oligometastatic disease
- Plurimetastatic disease if a particular site is causing painful symptoms or is at risk for pathologic fracture
You will not qualify if you...
- Life expectancy less than 3 months or severe functional status impairment (ASA 4)
- Hypovascular metastasis shown by angiography or MRI perfusion study with MDC
- Coagulation deficiency or plateletopenia
- Documented active infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants undergo arterial embolization as part of their treatment for bone metastases and are observed.
Regular visits for assessments over 1 year
Duration - Up to 1 year
Participants are followed to monitor pain reduction, quality of life improvements, and tumor volume changes after the embolization treatment.
Periodic visits for follow-up assessments up to 1 year
Trial Site Locations
Total: 1 location
1
Istituto Ortopedico Rizzoli
Bologna, Emilia-Romagna, Italy, 40136
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here